The Negative Checkpoint Receptor TIGIT Marks Exhausted T cells During SIV Infection and Correlates with SIV Disease Progression Gabriela Webb Vaccine and.

Slides:



Advertisements
Similar presentations
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
Advertisements

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
The Journal of Immunology, 2013 March 27; 190: , IF=5.52
José Pedro Lopes Exhausted CD3 CD8 TCR TIM3 1B11 LAG3 Generated in chronic antigen- mediated TCR stimulation. Express inhibitory receptors and lack effector.
Representing the Immune Epitope Database in OWL Jason A. Greenbaum 1, Randi Vita 1, Laura Zarebski 1, Hussein Emami 2, Alessandro Sette 1, Alan Ruttenberg.
Comparison between Pathogenic and Nonpathogenic SIV Infections and Focus on Mucosal Tissue Compartment Reveal a Critical Role for the.
2014 “Towards an HIV Cure” symposium Melbourne SIV infection of the macaque testis – an immune privileged site Wendy Winnall, University of Melbourne.
Instructions To use this template: –for each slide write the correct answer on the orange bar first –choose which option (A,B,C or D) and make sure you.
1 HIV Curative Strategies: Key Research Priorities Deeks S, et al., (2013) Nat Rev Immunol. 12(8):
Polyclonality & Initial HIV- specific CD4 clone size determine outcome of infection Hester Korthals Altes Lab. Immunologie Tissulaire et Cellulaire Hôpital.
High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection Abstract.
2014 “Towards an HIV Cure” symposium Melbourne The Immune Checkpoints PD-1, LAG-3 and TIGIT are Biomarkers of HIV Infected Cells During ART and Identify.
Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.
Pathogenesis of HIV disease and markers of progression Anjie Zhen, PhD.
Novel strategies for prevention and treatment of HIV infection Prasit Faipenkhong Pairoaj Vonghathaipaisarn Rodjana Chunhabundit Zhang Jianjun.
EFFECTOR FUNCTIONS OF HELPER T-LYMPHOCYTES. Dendritic cells use several pathways to process and present protein antigens.
Pavel Bostik FMHS Charles University Medical School University Hospital Hradec Kralove Czech Republic DIFFERENTIAL EFFECTS OF (LENTI)VIRUS INFECTION ON.
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
The Future of HIV/AIDS: The Road to a Cure. How HIV persists during therapy?  Ongoing viral replication occurs in subjects on suppressive HAART (TW Chun,
Lecture 6 clinical immunology Cytokines
Cancer immunotherapy: an update
Immunological tolerance and immune regulation -- 1
Alan L. Landay, PhD Professor and Chairman of Immunology, Microbiology, and Medicine Rush University Medical Center Chicago, Illinois On The Road to an.
Davey Smith, MD Professor of Medicine University of California San Diego La Jolla, California When Will It All Be Over? HIV Cure Efforts Los Angeles, California:
The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus by Richard Dunham, Paola Pagliardini, Shari.
G. E. Martin. , N. Pantazis. , M. Hoffmann. , S. Hickling, J. Hurst, J
Cancer immunotherapy: an update
Immune Regulation, Tolerance, and Autoimmunity
Summary and Conclusion Hypothesis and Rationale
Immunological tolerance and immune regulation -- 1
HIV Cure: Current Status and Future Perspectives
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Figure 3 Altered adaptive immune functions after sepsis
Volume 141, Issue 4, Pages e6 (October 2011)
Differentiation and Functions of CD8+ Effector T Cells
Nat. Rev. Urol. doi: /nrurol
Ana C. Anderson, Nicole Joller, Vijay K. Kuchroo  Immunity 
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
Nat. Rev. Rheumatol. doi: /nrrheum
by Scott G. Hansen, Helen L. Wu, Benjamin J. Burwitz, Colette M
Figure 1 The role of CTLA4 and PD1 in T cell activation
Checkpoint blockade therapy resistance in Hodgkin's lymphoma
Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy  Steven G. Deeks, Bruce D. Walker 
by Scott G. Hansen, Helen L. Wu, Benjamin J. Burwitz, Colette M
Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia  Saad S. Kenderian, MD, Marco Ruella, MD,
Aim What happens when a bacteria or virus mutates?
Nat. Rev. Endocrinol. doi: /nrendo
Study of HIV-2 in monkey Pigtail macaque (Macaca nemestrina) Baboons
Volume 24, Issue 6, Pages (June 2016)
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
Volume 26, Issue 4, Pages (April 2018)
Feeling Exhausted? Tuning Irf4 Energizes Dysfunctional T Cells
Volume 143, Issue 1, Pages (July 2012)
CD8+ T Cells and cART: A Dynamic Duo?
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Katherine A. Barraclough, E. Geoffrey Playford  Kidney International 
Janna Krueger, Christopher E. Rudd  Immunity 
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy
CD25+ proliferation and suppression are independent functional variables in type 1 diabetes. CD25+ proliferation and suppression are independent functional.
Figure 1. Longitudinal measures of HIV persistence and immunologic phenotype/function during anti-PD-1 therapy are ... Figure 1. Longitudinal measures.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
Association of HIV-1 replication fitness, as measured in a whole-virus parallel infection assay, with ability to control viremia after treatment interruption.
KEY CONCEPT Some viral diseases can be prevented with vaccines.
by Zaza M. Ndhlovu, Samuel W
BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment.
Immunologic strategies for HIV-1 remission and eradication
Presentation transcript:

The Negative Checkpoint Receptor TIGIT Marks Exhausted T cells During SIV Infection and Correlates with SIV Disease Progression Gabriela Webb Vaccine and Gene Therapy Institute Oregon Health and Science University July 21, 2015

CD8+ T cell TIGIT CD155 PD1 PDL1 Proliferation Cytokine production TCR Rhesus TIGIT shares 88.1% sequence homology with human TIGIT High antigenic load environment  T cell exhaustion

TIGIT expression is increased in SIV+ RMs and correlates with viral load

TIGIT is also found on SIV-specific CD8+ T cells in RMs with full cART suppression of SIV viremia SIV-specific CD8+ T cells co-express TIGIT & PD-1

TIGIT+ CD8+ T cells produce less IFNγ when stimulated Single and dual blockade of PDL1 and TIGIT restores CD8+ T cell proliferation Summary TIGIT is expressed on SIV-specific CD8+ T cells and proliferative capacity can be restored with single or dual blockade Rhesus TIGIT in SIV infection recapitulates what is observed with human TIGIT in HIV infection  Glen Chew (TUAA02 Rm ) TIGIT/PD1 blockade could be used in conjunction with “shock and kill” approaches

Acknowledgements Oregon Health & Science University Jonah Sacha Benjamin Burwitz Shaheed Abdulhaqq Helen Wu Jason Reed Katherine Hammond Reesab Pathak Scott Hansen University of Hawaii Lishomwa Ndhlovu Glen Chew – TUAA02 Tsuyoshi Fujita Bristol-Myers Squibb Alan Korman Mark Maurer